Cerebrolysin

What Cerebrolysin Is

Cerebrolysin is not a single peptide but a standardized mixture of low-molecular-weight neuropeptides and free amino acids derived from enzymatic and proteolytic hydrolysis of purified porcine brain tissue. It is manufactured by EVER Neuro Pharma (Austria) under the development code FPF-1070 and has been in clinical use in parts of Europe, Russia, China, and Asia since the 1970s. The active fraction consists of peptides below roughly 10 kDa that cross the blood-brain barrier at meaningfully higher efficiency than intact neurotrophins, plus a free-amino-acid fraction that appears to contribute to the observed pharmacology.

Because Cerebrolysin is a mixture rather than a defined chemical entity, its pharmacology is characterized at the level of the overall preparation rather than individual components — a regulatory posture that has kept it out of the FDA's approved-drug list despite decades of international clinical use.

Mechanism of Action

The working hypothesis developed over several decades of preclinical and clinical research is that Cerebrolysin mimics the effect of endogenous neurotrophic factors, particularly BDNF, NGF, CNTF, and GDNF. The observed effects in neuronal cell culture and animal models include:

• Neuroprotection against excitotoxic injury. Attenuation of glutamate-induced neuronal death, relevant to ischemic stroke models.
• Promotion of neurogenesis. Increased proliferation of hippocampal progenitor cells in aged and injured rodent brain.
• Synaptogenesis and dendritic remodeling. Upregulation of synaptic density markers in models of traumatic brain injury.
• Reduced amyloid pathology. In transgenic Alzheimer models, Cerebrolysin has been reported to reduce amyloid-beta plaque burden and tau hyperphosphorylation.

The exact identity of the peptide fragments responsible for each effect has not been fully resolved, which is one of the reasons Cerebrolysin remains difficult to evaluate against single-molecule comparators.

Clinical Evidence

The Cerebrolysin clinical literature is substantial but geographically concentrated. The strongest evidence exists in three indications:

• Acute ischemic stroke. The CASTA and CARS series of trials, conducted primarily across Eastern Europe and Asia, have reported modest but consistent improvements in neurological recovery when Cerebrolysin is added to standard care within the first hours to days of ischemic stroke.
• Traumatic brain injury. The CAPTAIN I and II trials examined moderate-to-severe TBI and reported favorable shifts on composite neurological recovery scales.
• Vascular and Alzheimer dementia. A Cochrane review of Alzheimer trials concluded that Cerebrolysin likely produces small short-term cognitive improvements, though the confidence intervals remain wide and most trials were short.

The methodological caveats are well known: heterogeneous dosing regimens across studies, open-label designs in many earlier trials, and limited independent replication outside the sponsor-funded investigator network.

Administration and Dosing

Cerebrolysin is administered intravenously (as a slow infusion) or intramuscularly. Standard hospital protocols in approved jurisdictions use 10 to 30 mL per day for 10 to 20 consecutive days, repeated in cycles for chronic neurodegenerative indications. Unlike most peptides in this library, it is supplied in solution rather than as lyophilized powder, and dose is specified by volume of the proprietary preparation rather than by milligrams of peptide.

Regulatory Status

Cerebrolysin is approved as a prescription medicine in over 40 countries across Europe, Asia, Latin America, and the former Soviet states. It has never been approved by the FDA or the EMA through centralized procedures. In the United States it is imported only through research channels or personal-import exemptions, and its use falls outside standard neurologic guidelines.

Safety Profile

The long post-marketing record in approved jurisdictions shows a generally favorable safety profile. Reported adverse events are mostly mild: injection-site reactions, transient agitation or insomnia, dizziness, and occasional nausea. Epilepsy is considered a relative contraindication based on isolated reports of seizure threshold lowering, and severe renal impairment is typically listed as a caution. For comparative context on neurotrophic peptides, see our Semax and Selank references.

Bottom Line

Cerebrolysin is a compositionally complex, clinically credible, and regulatorily fragmented product — widely used where approved, effectively unavailable through regulated channels in the US. The evidence base is real but not independently confirmed to the standard typical of single-molecule drug development.